Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid Marie Holst Olsen; Jens B Sørensen; Birgitte Federspiel; Andreas Kjaer; Carsten P Hansen; Ulrich Knigge; Seppo W Langer

doi:10.1100/2012/170496

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid Marie Holst Olsen, Jens B Sørensen, Birgitte Federspiel, Andreas Kjaer, Carsten P Hansen, Ulrich Knigge, Seppo W Langer

Research output: Contribution to journal › Journal article › Research › peer-review

70 Citations (Scopus)

Abstract

Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

Original language	English
Journal	Scientific World Journal
Volume	2012
Pages (from-to)	170496
Number of pages	4
ISSN	2356-6140
DOIs	https://doi.org/10.1100/2012/170496
Publication status	Published - 2012

Access to Document

10.1100/2012/170496

Library access?

Check availability at the Royal Danish Library

Cite this

@article{4bdfe17f293747a3b8ac8d2dd8da3ff3,

title = "Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas",

abstract = "Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.",

author = "Olsen, {Ingrid Marie Holst} and S{\o}rensen, {Jens B} and Birgitte Federspiel and Andreas Kjaer and Hansen, {Carsten P} and Ulrich Knigge and Langer, {Seppo W}",

year = "2012",

doi = "10.1100/2012/170496",

language = "English",

volume = "2012",

pages = "170496",

journal = "Scientific World Journal",

issn = "2356-6140",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

AU - Olsen, Ingrid Marie Holst

AU - Sørensen, Jens B

AU - Federspiel, Birgitte

AU - Kjaer, Andreas

AU - Hansen, Carsten P

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2012

Y1 - 2012

N2 - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

AB - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

U2 - 10.1100/2012/170496

DO - 10.1100/2012/170496

M3 - Journal article

C2 - 22973169

SN - 2356-6140

VL - 2012

SP - 170496

JO - Scientific World Journal

JF - Scientific World Journal

ER -